目的 探讨血清对氧磷酶1(PON1)联合白蛋白/球蛋白比值(AGR)对膀胱癌根治术后尿道复发的预测价值.方法 选取接受膀胱癌根治术的183例患者为研究对象,根据随访期间的尿道复发情况将患者分为复发组和未复发组,比较两组术前血清PON1、AGR水平及临床病理特征,采用多因素logistic回归分析膀胱癌根治术后尿道复发的危险因素;通过绘制受试者工作特征(ROC)曲线,分析术前血清PON1、AGR水平对膀胱癌根治术后尿道复发的预测价值.结果 随访期间3例失访,180例患者纳入研究,膀胱癌根治术后患者共有23例尿道复发,复发率12.78％.复发组术前血清PON1水平低于未复发组(P<0.05),复发组年龄、术前血清AGR水平高于未复发组(P<0.05),复发组肿瘤直径>3 cm、多发、临床分期T3a～T4a期、病理分级为高级别、侵犯前列腺、接受非原位可控尿道改道术患者占比均高于未复发组(P<0.05).多因素logis-tic回归分析显示:年龄、肿瘤直径>3 cm、临床分期T3a～T4a期、病理分级为高级别、侵犯前列腺、接受非原位可控尿道改道术及术前血清低PON 1水平、术前血清高AGR水平均是膀胱癌根治术后尿道复发的危险因素(P<0.05).术前血清PON1、AGR单独及二者联合预测膀胱癌根治术后尿道复发的曲线下面积(AUC)分别为0.803、0.881、0.897.结论 术前血清PON1水平降低和AGR水平升高均是膀胱癌根治术后尿道复发的危险因素,术前血清PON 1和AGR可作为预测此类患者术后尿道复发的辅助指标.

Objective:To explore the relationship between epithelial-mesenchymal transition (EMT) and ureteral stricture after holmium laser lithotripsy for ureteral calculi.Methods:A total of 34 patients with ureteral stricture after holmium laser lithotripsy for ureteral calculi in The First Affiliated Hospital of Henan University of Science and Technology between June 2019 and June 2021 were selected as the stricture group, including 19 males and 15 females, with an age of (44.54±10.35) years old. Another 34 patients without ureteral stricture after ureteral holmium laser lithotripsy during the same period were regarded as the non-stricture group according to the ratio of 1:1, including 20 males and 14 females, with an age of (45.56±9.57) years old. χ2 test or independent sample t test was used to compare the general data and serum levels of high mobility group protein B1 (HMGB1), interleukin-1β (IL-1β), and transforming growth factor-β1 (TGF-β1) between the two groups, and the receiver operating characteristic curve (ROC) was used to analyze the predictive efficacies of serum HMGB1, IL-1β, and TGF-β1 levels in ureteral stricture after holmium laser lithotripsy. Results:Before surgery, there were no statistically significant differences in the serum HMGB1, IL-1β, and TGF-β1 levels between the two groups (all P>0.05); on the postoperative 7th day, the serum levels of HMGB1, IL-1β, and TGF-β1 in the stenosis group were (15.98±1.11) μg/L, (24.23±1.54) μg/L, and (381.58±38.52) ng/L, which were higher than those in the non-stenosis group [(14.21±1.02) μg/L, (23.11±1.08) μg/L, and (318.23±27.54) ng/L], with statistically significant differences (all P<0.05). The ROC analysis showed that serum levels of HMGB1, IL-1β, and TGF-β1 on the postoperative 7th day could be used as predictors for ureteral stenosis after holmium laser lithotripsy ( Z=7.421, 2.759, and 10.740; all P<0.05), the area under the curve (AUC) was 0.848, 0.679, and 0.898, respectively, and serum TGF-β1 had the highest predictive efficiency. Conclusions:Ureteral injury caused by holmium laser lithotripsy can lead to the increases of serum HMGB1, IL-1β, and TGF-β1 levels. Patients' serum HMGB1, IL-1β, and TGF-β1 levels can be used as predictors for ureteral stricture after holmium laser lithotripsy.

Introduction Ribosome binding protein 1 (RRBP1) is reported to be correlated with tumor formation and progression. However, the role of RRBP1 in bladder cancer is unclear. In this study, we aimed to investigate the expression of RRBP1 and its influence on cell proliferation in bladder cancer. Methods Quantification real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were used to detect the expression levels of RRBP1 in 138 bladder cancer and matched adjacent normal bladder tissues. Then, the clinical significance of RRBP1 in bladder cancer was evaluated. The effect of RRBP1 on cell proliferation and its potential mechanism were further explored. Results Results show that the mRNA levels of RRBP1 in bladder cancer were significantly higher compared with those in normal tissues (P< 0.001). IHC results show the high-expression rate of RRBP1 in bladder cancer was 68.8%, which was significantly greater than those in normal tissues (40.6%, P< 0.001). RRBP1 high-expression was significantly associated with differentiation, T stage and lymph node metastasis in bladder cancer (P< 0.05). The overall survival time of patients with RRBP1 high-expression was significantly reduced compared to those with RRBP1 low-expression. Moreover, RRBP1 overexpression significantly promoted cell proliferation, which was correlated with Smad1/Smad3/TGF-β1 signal pathway. Conclusion RRBP1 high-expression correlates with prognosis and promotes cell proliferation in bladder cancer, which could be a potential biomarker.